Dr. Thomas E. Stinchcombe, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Virginia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NC license 9800708 -
Hematology & Oncology Physician
NC license 9800708
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
- Duke Regional Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 520
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 122 | 67 |
| Established patient office or other outpatient visit, 30-39 minutes | 64 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 45 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 92 |
| Alecensa (alectinib hcl) | 31 |
| Prochlorperazine Maleate Other prescribers in Chapel Hill, NC | 25 |
| Retevmo (selpercatinib) | 15 |
| Dexamethasone Other prescribers in Chapel Hill, NC | 14 |
| Erlotinib Hcl | 13 |
| Everolimus | 13 |
| Mekinist (trametinib dimethyl sulfoxide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 19 payments worth $25,458 in total to this clinician.
| Pfizer Inc. | $8,634 |
|---|---|
| F. Hoffmann-la Roche AG | $6,080 |
| AstraZeneca UK Limited | $2,870 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,220 |
| Coherus Oncology, Inc. | $1,400 |
| Acrotech Biopharma Inc. | $1,350 |
| Merck Sharp & Dohme LLC | $1,220 |
| Gilead Sciences, Inc. | $760 |
| Consulting Fee | $18,294 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,200 |
| Honoraria | $700 |
| Food and Beverage | $264 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $6,200 |
| AstraZeneca UK Limited Nov 7, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,870 |
| F. Hoffmann-la Roche AG Apr 1, 2025 | Consulting Fee | $2,280 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 25, 2025 | Consulting Fee | $2,220 |
| F. Hoffmann-la Roche AG Jul 8, 2025 | Consulting Fee | $1,900 |
| F. Hoffmann-la Roche AG Dec 12, 2025 | Consulting Fee | $1,900 |
| Merck Sharp & Dohme LLC Jul 7, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,220 |
| Pfizer Inc. Sep 10, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $1,134 |
| Gilead Sciences, Inc. Apr 16, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4071973;GTF;10949425 | $760 |
| Acrotech Biopharma Inc. Dec 4, 2025 | Consulting Fee | $750 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 29, 2025 | Consulting Fee | $650 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee | $650 |
| F. Hoffmann-la Roche AG Dec 12, 2025 | Consulting Fee | $1,900 |
| Pfizer Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) ABRYSVO · VACCINES | $6,200 |
| Acrotech Biopharma Inc. Dec 4, 2025 | Consulting Fee | $750 |
| AstraZeneca UK Limited Nov 7, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,870 |
| Pfizer Inc. Sep 10, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $1,134 |
| F. Hoffmann-la Roche AG Jul 8, 2025 | Consulting Fee | $1,900 |
| Merck Sharp & Dohme LLC Jul 7, 2025 | Consulting Fee ONCOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $1,220 |
| Gilead Sciences, Inc. Apr 16, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4071973;GTF;10949425 | $760 |
| F. Hoffmann-la Roche AG Apr 1, 2025 | Consulting Fee | $2,280 |
| Coherus Oncology, Inc. Mar 31, 2025 | Honoraria LOQTORZI · Oncology | $700 |
| Coherus Oncology, Inc. Mar 31, 2025 | Consulting Fee LOQTORZI · Oncology | $700 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Mar 25, 2025 | Consulting Fee | $2,220 |
| Genentech, Inc. Jan 16, 2025 | Consulting Fee Tecentriq · BioOncology | $660 |
| Acrotech Biopharma Inc. Jan 6, 2025 | Consulting Fee | $600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 6 companies. The companies reported $488,376 in research payments for these studies, mostly to the institutions running them.
- Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim Pharma GmbH & Co.kg - Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim Pharmaceuticals, Inc. - Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics, Inc. · Recruiting · NCT04613596 - A phase 2 basket study of tucatinib in combination with trastuzumab in subjects with previously treated locallyadvanced unresectable or metastatic solid tumors driven by HER2 alterations
Pfizer Inc. - Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
Boehringer Ingelheim Espana S.a. - A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic No…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.